Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dana Ambler

Reproductive Endocrinology Englewood, CO Doctor of Osteopathy

NPI 1396943965 CMS profile 244656

9780 Pyramid Ct. Suite 260, Englewood, CO 80112

Open in the dashboard

General payments

$1,137

64 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Ambler of Englewood, CO is reported in the CMS Open Payments database as having received $1,137 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29 2
2024 General $214 8
2023 General $83 5
2022 General $161 9
2021 General $110 8
2020 General $162 8
2019 General $379 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Ambler
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Dana Ambler were reported at $29. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Dana Ambler Reproductive Endocrinology median Middle half National median
2019 $379 $196 $77–$425 $163
2020 $162 $81 $35–$182 $114
2021 $110 $102 $43–$247 $132
2022 $161 $139 $62–$303 $149
2023 $83 $141 $65–$285 $160
2024 $214 $144 $65–$302 $164
2025 $29 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ferring Pharmaceuticals Inc. $490 27 payments
  2. Organon LLC $173 13 payments
  3. AbbVie, Inc. $138 7 payments
  4. Amneal Pharmaceuticals LLC $72 4 payments
  5. EMD Serono, Inc. $67 3 payments
  6. Meditrina $45 2 payments
  7. CooperSurgical, Inc. $43 2 payments
  8. Hologic, LLC $37 2 payments
  9. Galen US Inc $22 1 payment
  10. Daiichi Sankyo Inc. $18 1 payment
  11. Other $31 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,127 63 payments
  2. Education $10 1 payment
Products named General payments · program years 2019–2025
  1. MENOPUR Reproductive Health $376 21 payments
  2. FOLLISTIM AQ $156 9 payments
  3. Orilissa Endocrinology $82 4 payments
  4. MENOPUR Reproductive Health $78 3 payments
  5. UNITHROID $72 4 payments
  6. ORILISSA Womens Health $39 2 payments
  7. Gonal-f $35 2 payments
  8. IVF Products $31 1 payment
  9. Aveta System $25 1 payment
  10. MYOSURE TISSUE REMOVAL DEVICE $23 1 payment
  11. Other $201 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record